New Research Suggests Local Treatment May Benefit Metastatic Prostate Cancer Patients

This graphic shows the significant difference in 5-year overall survival rates between patients who received local treatments (radical prostatectomy at 67.4% and brachytherapy at 52.6%) compared to those who received no surgical or radiation treatment (22.5%).

New Research Suggests Local Treatment May Benefit Metastatic Prostate Cancer Patients

For Immediate Release - Prostate Cancer Support Group Newsletter

In a potentially practice-changing development, new research suggests that treating the primary tumor in men with metastatic prostate cancer may significantly improve survival rates, challenging current treatment protocols.

A recent study published in Nature Reviews Urology by researchers Lorenzo Tosco and Hendrik Van Poppel from University Hospitals Leuven has found that patients with metastatic prostate cancer who received local treatments had substantially better survival outcomes than those who didn't.

Surprising Survival Benefits

The retrospective analysis examined data from over 8,000 patients in the Surveillance Epidemiology and End Results (SEER) database. The findings were striking: men who underwent radical prostatectomy had a 67.4% five-year survival rate, while those who received brachytherapy achieved a 52.6% survival rate. In comparison, patients who received neither surgical nor radiation treatment had only a 22.5% five-year survival rate.

"This is potentially game-changing information for men diagnosed with metastatic prostate cancer," said Dr. James Wilson, medical advisor to our support group (not affiliated with the study). "While current guidelines recommend only hormonal therapy for metastatic disease, this research suggests we may need to rethink that approach."

Understanding the Science

The researchers explain that the primary tumor might serve as a "reservoir" of cancer cells that can continuously seed new metastases throughout the body. By removing or treating this reservoir, doctors may help reduce the spread of cancer, even when it has already metastasized.

This concept aligns with what the researchers call a "self-seeding" process - a circular exchange of cancerous cells between distant lesions and the primary tumor.

Age Considerations

The study also found that age plays a role in treatment outcomes. Patients younger than 70 who received local treatment showed better disease-specific survival than those 70 or older, particularly in the radical prostatectomy group.

Looking Ahead

While these findings are promising, the researchers caution that the retrospective nature of the analysis may limit its strength, and selection bias could have influenced the results.

The medical community is now looking toward future clinical trials to confirm these observations. A phase II trial (NCT01558427) is currently recruiting patients with oligometastatic prostate cancer to evaluate androgen-deprivation-therapy-free survival after maximal local treatment.

"If confirmed by clinical trials, the treatment approach for metastatic prostate cancer could change dramatically," notes the newsletter's medical correspondent. "This could open promising new options for patients with this serious condition."

As always, patients should discuss all treatment options with their healthcare providers, as individual cases vary and these findings are still considered preliminary.

Paper Summary

"The role of local therapy for metastatic prostate cancer" by Lorenzo Tosco and Hendrik Van Poppel, published in Nature Reviews Urology in February 2014. DOI: 10.1038/nrurol.2014.33

The article discusses the potential benefits of local treatments (such as radical prostatectomy or brachytherapy) for patients who have metastatic prostate cancer at diagnosis, which is traditionally managed with hormonal therapy alone.

Key points from the article include:

  1. Current guidelines recommend hormonal treatment as first-line therapy for metastatic prostate cancer, with local therapy typically reserved only for symptom control.
  2. A retrospective analysis of the SEER database involving 8,185 patients showed significantly better 5-year overall survival rates for patients who received local therapy (67.4% for radical prostatectomy and 52.6% for brachytherapy) compared to patients who received no surgical or radiation treatment (22.5%).
  3. The primary tumor may serve as a reservoir of potentially metastatic cells that can seed additional metastases, suggesting a biological rationale for treating the primary tumor.
  4. The authors note that these findings, while promising, come from retrospective analyses that may have selection bias.
  5. Age appears to be a factor, with better disease-specific survival in treated patients under 70 years compared to those 70 or older.
  6. The authors call for randomized clinical trials to confirm these observational findings, which could potentially change the treatment approach for metastatic prostate cancer.

The article was authored by researchers from University Hospitals Leuven in Belgium, and is part of a "News & Views" section of the journal.

 

Comments

Post a Comment

Popular posts from this blog

A 10-Second Steam Blast: The New Weapon Against Prostate Cancer?

Image
Vanquish® Water Vapor Ablation System, Francis Medical Steams Out Prostate Cancer The Vanquish® Water Vapor Ablation System, developed by Francis Medical, Inc. , represents an innovative approach to treating prostate cancer using water vapor (steam) to ablate cancerous tissue. This minimally invasive technique aims to target and destroy prostate cancer cells while minimizing damage to surrounding healthy tissue, potentially reducing common side effects associated with traditional treatments like surgery and radiation, Mechanism of Action:  The Vanquish system utilizes the thermal energy stored in sterile water vapor to ablate cancerous prostate tissue. During the procedure, a catheter is inserted through the urethra into the prostate, delivering water vapor directly to the targeted tissue. As the vapor condenses back into liquid, it releases stored thermal energy, effectively destroying the cancerous cells. This method is designed to respect the prostate's natural boundaries, ...
Read more

Researchers develop low-cost device that detects cancer in an hour | ScienceDaily

Image
Summary Sanjay S. Timilsina , currently Lead Scientist, StataDx, a spinoff from Wyss Institute, former Postdoctoral Fellow at Harvard Medical School and the Wyss Institute at Harvard University, PhD from UTEP Department of Chemistry & Biochemistry, and XiuJun Li full Professor in the Department of Chemistry and Biochemistry and of Forensic Science, & Environmental Science and Engineering, at the University of Texas at El Paso (UTEP) have developed a new portable device for cancer detection that offers several advantages over traditional methods: Key Features: - Low cost (a few dollars per device, <8 cents per assay) - Provides results in about 1 hour (vs. 12-16 hours for traditional methods) - Approximately 10 times more sensitive than traditional methods - Portable and doesn't require specialized instruments - Can detect both CEA colorectal and PSA prostate cancer biomarkers - Uses a "paper-in-polymer-pond" structure to analyze blood samples How it works: - U...
Read more

Cancer patients and doctors team up to change how cancer drugs are tested | Fox News

Cancer patients and doctors team up to change how cancer drugs are tested | Fox News foxnews.com Associated Press For cancer patients, the harsh side effects of powerful drugs have long been the trade-off for living longer. Now, patients and doctors are questioning whether all that suffering is necessary. They’ve ignited a movement to radically change how new cancer drugs are tested, with the U.S. Food and Drug Administration urging drugmakers to do a better job at finding the lowest effective dose, even if it takes more time. Advances in treatment mean millions of people are surviving for years with incurable cancers. Jill Feldman, 54, of Deerfield, Illinois, has lived 15 years with lung cancer , thanks to that progress. Her parents both died of lung cancer months after their diagnoses. But her cancer drug causes joint pain, fatigue and mouth sores that m...
Read more